Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly, Sitryx Enter Autoimmune Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Lilly, Sitryx Enter Autoimmune Alliance

To develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eli Lilly and Co. entered an exclusive global licensing and research collaboration with Sitryx, a biopharma company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. The collaboration will study up to four preclinical targets identified by Sitryx that could lead to potential new medicines for autoimmune diseases.

Sitryx will receive $50 million upfront and Lilly will make a $10 million equity investment in Sitryx. Sitryx will be eligible to receive potential development milestones up to $820 million, as well as commercialization milestones and royalties on potential sales.

Sitryx will grant Lilly an exclusive, worldwide license to develop and commercialize up to four immunometabolism targeted therapeutics, including Sitryx’s two lead projects. The companies will establish a five-year R&D collaboration, with Sitryx responsible for drug discovery, while Lilly will fund and manage the clinical development and commercializaton.

This transaction is subject to customary closing conditions. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics